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Differential ccr7 Targeting in 
Dendritic cells by Three naturally 
Occurring cc-chemokines
Gertrud M. Hjortø1†‡, Olav Larsen1‡, Anne Steen1‡, Viktorija Daugvilaite1, Christian Berg1, 
Suzan Fares1, Morten Hansen2, Simi Ali3 and Mette M. Rosenkilde1*
1 Department of Neuroscience and Pharmacology, Faculty of Health and Medical Sciences, The Panum Institute, University 
of Copenhagen, Copenhagen, Denmark, 2 Department of Haematology, Center for Cancer Immune Therapy (CCIT), 
Copenhagen University Hospital, Herlev, Denmark, 3 Medical Faculty, Institute of Cellular Medicine, Newcastle University, 
Newcastle upon Tyne, UK
The CCR7 ligands CCL19 and CCL21 are increasingly recognized as functionally different 
(biased). Using mature human dendritic cells (DCs), we show that CCL19 is more potent 
than CCL21 in inducing 3D chemotaxis. Intriguingly, CCL21 induces prolonged and more 
efficient ERK1/2 activation compared with CCL19 and a C-terminal truncated (tailless) 
CCL21 in DCs. In contrast, tailless-CCL21 displays increased potency in DC chemotaxis 
compared with native CCL21. Using a CCL21-specific antibody, we show that CCL21, 
but not tailless-CCL21, accumulates at the cell surface. In addition, removal of sialic acid 
from the cell surface by neuraminidase treatment impairs ERK1/2 activation by CCL21, 
but not by CCL19 or tailless-CCL21. Using standard laboratory cell lines, we observe 
low potency of both CCL21 and tailless-CCL21 in G protein activation and β-arrestin 
recruitment compared with CCL19, indicating that the tail itself does not improve receptor 
interaction. Chemokines interact with their receptors in a stepwise manner with ultimate 
docking of their N-terminus into the main binding pocket. Employing site-directed 
mutagenesis we identify residues in this pocket of selective CCL21 importance. We also 
identify a molecular switch in the top of TM7 important for keeping CCR7 in an inactive 
conformation (Tyr312), as introduction of the chemokine receptor-conserved Glu (or Ala) 
induces high constitutive activity. Summarized, we show that the interaction of the tail 
of CCL21 with polysialic acid is needed for strong ERK signaling, whereas it impairs 
CCL21-mediated chemotaxis and has no impact on receptor docking consistent with 
the current model of chemokine:receptor interaction. This indicates that future selective 
pharmacological targeting of CCL19 versus CCL21 should focus on a differential 
targeting of the main receptor pocket, while selective targeting of tailless-CCL21 versus 
CCL21 and CCL19 requires targeting of the glycosaminoglycan (GAG) interaction.
Keywords: ccr7, ccl19, ccl21, tailless-ccl21, dendritic cell, biased signaling, erK
inTrODUcTiOn
Chemokines are chemotactic cytokines that are vital for the immune system, especially as 
mediators of immune cell recruitment to sites of inflammation. The chemokine receptors, mainly 
expressed on leukocytes, belong to the largest class of proteins in the human genome, namely, seven 
transmembrane (7TM) G protein-coupled receptors (also known as GPCRs). The chemokines 
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are organized into groups according to the spacing between 
two conserved cysteine residues. This gives rise to four groups: 
CC, CXC, XC, and CX3C chemokines, with the number of Xs’ 
indicating the number of amino acids separating the conserved 
cysteines. The chemokine system is very promiscuous in that 
one ligand can bind to one or more receptors and vice  versa. 
The chemokines CCL19 and CCL21 [previously known as 
EBI1-ligand chemokine (ELC) and secondary lymphoid tissue 
chemokine (SLC), respectively] are the only ligands for CCR7 
(1–3); a receptor expressed on different subsets of immune cells 
(4), and involved in the homing of naive T cells and antigen-
presenting dendritic cells (DCs) to the lymph nodes. In the 
lymph nodes, DC–T cell priming takes place to allow antigen-
specific T-cell activation (5). In addition to its role in protective 
immunity, the CCR7:CCL19/CCL21 axis is also believed to be 
important for the architecture of the thymus (6, 7) and for the 
induction of peripheral tolerance (5, 8).
Although CCL19 and CCL21 bind to the same receptor, they 
are differentially expressed; i.e., CCL19 is secreted by mature 
DCs, whereas CCL21 is secreted from the endothelium of affer-
ent lymphatic vessels, and they both are present in the lumen 
of high endothelial venules (HEVs) and in stromal cells of the 
lymph node (9–11). CCL19 and CCL21 only share 32% amino 
acid identity, and importantly CCL21 has a large C-terminal tail 
of 37 amino acids that is highly positively charged and capable 
of strong binding to glycosaminoglycans (GAGs) causing 
chemokine immobilization (12, 13). CCL19 lacks this C-terminal 
domain and has poor affinity for GAGs. Due to their differential 
expression pattern and structural differences, it was early specu-
lated that CCL19 and CCL21 binding to CCR7 would induce 
distinct cellular responses (9–12). Moreover, it was recently 
shown that the tail of CCL21 causes the chemokine to adopt an 
auto-inhibited conformation in the absence of polysialic acid 
interaction (14). Finally, a tailless version of CCL21 was recently 
shown to be generated naturally through cleavage of full-length 
CCL21 initiated by endogenous proteases released by DCs (15), 
indicating that so far, three configurations of CCR7 activity can 
be anticipated in this cell type.
The canonical signaling for GPCRs is via coupling to het-
erotrimeric G proteins, which in turn are activated and initiate 
downstream signaling pathways. However, in the recent years, it 
has been shown that intracellular signaling also occurs follow-
ing β-arrestin-mediated internalization (16). The knowledge of 
diversity in signaling pathways, has opened up for the concept 
of biased signaling, which involves a preference for one signaling 
pathway over another, e.g., G protein versus β-arrestin coupling. 
It can be considered as either receptor bias (where the same 
ligand has different actions through different receptors), ligand 
bias (where two or more ligands act on the same receptor and 
induce different outcomes), or tissue bias (where the cellular 
effect depends on the tissue/cell type) (17, 18). Ligand bias by 
CCL19 and CCL21 at CCR7 has previously been described with 
regard to G protein coupling, β-arrestin recruitment, and recep-
tor internalization in various stably transfected cell lines (19–22). 
In addition, differential tissue expression of CCL19 and CCL21 
along with GAG accumulation of CCL21, polysialic acid control 
of full-length CCL21 activity, and local enzymatic cleavage of 
CCL21 to generate tailless-CCL21, is expected to confer tissue 
bias to CCR7.
For future therapeutic initiatives, it is important to under-
stand the roles of CCL19 and CCL21 in shaping immune cell 
migration and activation to potentially separate good and bad 
effects of CCR7 activity and target it accordingly. Here we inves-
tigate CCL19 and CCL21 for their ability to induce chemotaxis 
of human monocyte-derived DCs. As migration has classically 
been linked to ERK activation, we investigate the effect of CCL19 
and CCL21 on CCR7 signaling through this pathway in DCs 
and assess the influence of sialic acid residues on ERK activ-
ity and migration. To delineate a possible role of the elongated 
C-terminal basic tail of CCL21 in CCR7 signaling, we evalu-
ate the potency of a tailless version of CCL21 in inducing DC 
migration and ERK activation, and also assess CCL19, CCL21, 
and tailless-CCL21 for their abilities to differentially activate 
CCR7 with respect to various intracellular effectors, includ-
ing G protein activation, β-arrestin recruitment, and receptor 
internalization. Finally, through a mutational scan, we search 
for residues in CCR7 of differential importance for CCL19 or 
CCL21 in order to determine structural differences controlling 
receptor docking of their respective N-termini into the main 
binding pocket of CCR7.
MaTerials anD MeThODs
Materials
The human chemokines CCL19 and CCL21 were purchased 
from R&D systems and PeproTech (Accession # Q99731.1 
and Q6ICR7, respectively). Tailless-CCL21 was from ALMAC 
(sequence SDGGAQDCCL KYSQRKIPAK VVRSYRKQEP 
SLGCSIPAIL FLPRKRSQAE LCADPKELWV QQLMQHLDKT 
PSPQKPAQG). Goat anti-human CCL21 was from R&D systems 
(Cat. no. AF366). The human CCR7 cDNA was cloned from a 
spleen-derived cDNA library. The promiscuous chimeric G 
protein GαΔ6qi4myr (Gqi4myr) that converts Gαi-related signaling 
into a Gαq readout (23, 24) was kindly provided by Evi Kostenis 
(University of Bonn, Germany). Antibodies against p44/42 MAPK 
(ERK1/2) and phosphorylated p44/42 MAPK (ERK1/2, Thr202/
Tyr204) were purchased at Cell Signaling. Neuraminidase (NA) 
was from Sigma.
Transfections and cell culture
HEK293 cells were grown at 10% CO2 and 37°C in Dulbecco’s 
modified Eagle’s medium 1885 supplemented with 10% 
fetal bovine serum, 2 mM glutamine, 180 U/ml penicillin, and 
45 μg/ml streptomycin. PathHunter U2OS β-Arrestin 2 Parental 
cell line (DiscoveRx, Birmingham, United Kingdom) were grown 
at 5% CO2 and 37°C in MEMα Glutamax medium supplemented 
with 10% fetal bovine serum, 180  U/ml penicillin, 45  μg/ml 
streptomycin, and 0.25  μg/ml Hygromycin B (Invitrogen). 
Transient transfection of HEK293 cells for phosphatidylinositol 
(PI)-turnover was performed using the calcium phosphate pre-
cipitation method as previously described (25, 26). U2OS cells 
were transfected using FuGENE® 6 Transfection reagent (Roche, 
Mannheim, Germany).
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Phosphatidylinositol-Turnover
HEK293 cells were cotransfected with receptor cDNA and Gqi4myr, 
which converts the Gαi signal into a Gαq signal, making it possible 
to measure the chemokine receptor activation as PI-turnover (23, 
24). One day after transfection, the cells were seeded in 96-well 
plates (3.5  ×  104  cells/well) and incubated with 0.65  μCi of 
3H-myo-Inositol in 0.1 ml growth medium for 24 h. Cells were 
washed twice with Hank’s buffered salt solution (HBSS) supple-
mented with CaCl2 and MgCl2 and incubated for 15 min in 0.1 ml 
buffer supplemented with 10 mM LiCl prior to ligand addition 
followed by 90 min incubation. The generated [3H]inositol phos-
phate was detected directly by addition of SPA-YSI bead solution. 
Determinations were made in duplicates.
β-arrestin recruitment assay
Recruitment of β-arrestin was measured using the PathHunter™ 
β-arrestin assay (DiscoveRx). CCR7 was fused with the ProLink™ 
(PK) 1-tag [a small fragment of the enzyme β-galactosidase (β-
gal), the enzyme donor] and cloned into a pCMV-vector. Assays 
were performed in a U2OS cell line stably expressing β-arrestin 
2 coupled to the large β-gal fragment (enzyme acceptor). Cells 
were seeded in 96-well plates, 20,000 cells/well, and transfected 
the following day with 50  ng DNA using FuGENE® 6 reagent 
(0.15 μl/well). Twenty-four hours after transfection, the medium 
was removed and 100 μl Opti-MEM® I (Gibco®) was added. The 
following day, cells were stimulated with varying concentrations 
of ligand for 90 min at 37°C. The Detection Reagent Solution® 
was added prior to 60 min incubation at room temperature and 
the β-arrestin recruitment was measured as chemiluminescence 
using Perkin Elmer EnVision 2104 Multilabel Reader.
internalization
The internalization of CCR7 was measured in the U2OS cell line 
from DiscoveRx. The cells coexpressed enzyme acceptor-tagged 
β-arrestin 2 and a PK-tag linked to endofin, which is localized 
to endosomes. The experiment was carried as described for the 
β-arrestin recruitment assay, yet with 3  h incubation with the 
ligands.
Dc Maturation
Monocyte-derived DCs (DCs) were prepared by plastic adhesion 
from peripheral blood mononuclear cells (PBMCs) kindly pro-
vided by Professor Inge Marie Svane, Herlev Hospital, Denmark. 
The monocytes were differentiated into immature DCs in X-Vivo 
medium supplemented with 1000 U/ml GM-CSF and 250 U/ml 
IL-4 for 6 days, followed by maturation for 2 days with 1000 U/ml 
TNF-α, IL-1β, and IL-6 plus 1 μg/ml PGE2. Harvest of DCs was 
performed by medium aspiration followed by cold incubation 
of remaining cells in PBS with EDTA (5 mM) and subsequent 
scraping of cells followed by freezing of DCs in aliquots.
Measurement of erK Phosphorylation 
(Mesoscale Multisport assay)
Mature DCs were seeded in 96-well plates (8.0 × 104 cells/well). 
DCs were incubated for 2  h at 37°C, 5% CO2 before addition 
of chemokine and incubation at 37°C for 10  min. Following, 
the cells were lysed and prepared for measurement of ERK1/2 
phosphorylation by using the Meso Scale Discovery (MSD)® 
MULTI-SPOT Assay system Phospho (Thr202/Tyr204; Thr185/
Tyr187)/Total ERK1/2 Assay (Meso Scale Discovery, MD, USA) 
according to the manufacturer’s instructions. Determinations 
were made in duplicates and measurements were performed on 
MSD SECTOR Imager.
Measurement of erK Phosphorylation 
(Western Blot)
Mature DCs were washed twice in serum-free X-vivo medium 
and incubated in this medium for 2  h at RT to starve them 
from serum factors. In experiments with NA treatment, the 
enzyme was added during this incubation at a concentration of 
2.5 × 10−2 U/ml and the cells kept at 5% CO2 and 37°C. The cells 
were seeded in 96-well plates (8 × 104 cells/well) and stimulated 
with CCL19, CCL21, or tailless-CCL21 for the indicated time 
period. The cells were lysed in ice-cold RIPA buffer (Millipore) 
with protease (mini complete Roche) and phosphatase inhibi-
tors (mix 2 and 3, Sigma). The lysates were run on SDS-gel and 
transferred to PVDF for detection of total and phosphorylated 
ERK1/2.
ibidi® 3D Migration assay
The Ibidi® assay was carried out according to the manufacturer. 
Briefly, the collagen mixture was prepared and DCs were added 
to a final concentration of 0.5 to 1 × 106 cells/ml. The cell/col-
lagen mixture was loaded into the Ibidi channel, according to 
the protocol, and left to polymerize for 35  min in a 5% CO2, 
humidified incubator at 37°C. The final collagen concentration 
was 1.67  mg/ml. Finally the source and sink reservoirs were 
filled with medium containing 2% human serum with or without 
chemokine, respectively, and the slide with loaded DCs was 
mounted on a computer controlled stage, holding a temperature 
controlled (37°C), humidified incubation chamber with 5% CO2. 
DC migration was followed for 12 h by time-lapse microscopy 
using a time interval of 2  min. Cell migration (approximately 
20–40 cells) was tracked using a commercial tracking program 
(Autozell) and subsequently analyzed to get a population-based 
chemotactic index (CI) value (MATLAB). CI is a measure of 
net translocation distance to the source relative to total distance 
traveled.
immunostainings
In order to determine ligand surface localization, DCs were 
stained and fixed in suspension by incubating in serum-free 
medium with or without 100 nM CCL21, or tailless-CCL21 for 
30 min on ice, followed by washing in PBS and fixation for 15 min 
in 3.7% formaldehyde in PBS. After fixation the cells were washed 
and incubated for 1 h with primary anti-human CCL21 antibody. 
The DCs were washed and incubated with secondary rabbit 
anti-goat antibody (Alexa-488 coupled) for 1 h. The DCs were 
washed, in PBS, with an additional final wash in sterile water and 
resuspended in 70% ethanol. DCs were mounted on microscope 
slides and sealed under coverslides.
FigUre 1 | 3D chemotaxis of human dendritic cells (Dcs) in response 
to ccl19 and ccl21. Human DCs naturally expressing CCR7 were used 
for the 3D chemotaxis assay. In this assay, a collagen filled channel with the 
cells is in contact with a source and sink reservoir on either side, causing the 
cells to experience a linear gradient as chemokine gradually diffuses from 
source to sink. (a) Column diagrams showing the directional migration of 
DCs in response to either 10 nM (left) or 100 nM (right) CCL19 or CCL21 
source concentrations. The values are calculated as chemotactic index (CI) in 
the MATLAB software. (B) Spider diagrams depicting the migration pattern in 
response to the indicated concentrations of the chemokines. Statistical 
significance was calculated using unpaired t test. NS, not significant; 
*P < 0.05 (n = 3).
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elisa
CCL21 and tailless-CCL21 were adsorped on Maxisorp plates in 
PBS buffer over night at 4°C. The wells were washed three times 
in PBS and incubated for 60  min in blocking buffer (PBS, 1% 
BSA) at room temperature. Wells were incubated for 60 min with 
primary goat anti-CCL21 antibodies in blocking buffer. After 
PBS washing, the wells were incubated with secondary rabbit 
anti-goat HRP antibodies for 60 min. After PBS washing, TMB 
substrate was added. The reaction was stopped with H2SO4 0.2M 
and absorbance at 450 was read in an Envision plate reader.
calculations
IC50, EC50, and Kd/Ki values were determined by non-linear 
regression and Bmax values were calculated using the GraphPad 
Prism 4.0 software (GraphPad, San Diego, CA, USA).
statistical analysis
Statistical significance was calculated using unpaired t test, and 
data are represented as mean ± SEM. Significance is indicated as 
follows: NS, not significant; *P < 0.05; **P < 0.01.
resUlTs
Decreased response to ccl21 in 3D 
chemotaxis of human Dcs
To assess the relative importance of the two CCR7 ligands in 
stimulating various DC responses, we investigated the effect of 
CCL19 and CCL21 on a range of biological readouts. One very 
important readout in immune cell biology is the ligand-controlled 
migration of cells toward physiologically relevant ligands. We 
measured chemotaxis of human monocyte-derived DCs induced 
by either CCL19 or CCL21 using Ibidi® 3D chemotaxis slides. At 
10 nM, CCL21 induced a migration response characterized by a 
significantly lower CI compared with CCL19. However, at 100 nM 
chemokine concentrations, the cells migrated with equal direc-
tionality (CI) toward the two ligands (Figure 1A). The migration 
patterns are depicted in the spider diagrams (Figure 1B), which 
show that DC migration is less directional in response to CCL21 
compared with CCL19 at low concentrations (10 nM).
superior MaP Kinase activation by ccl21 
compared with ccl19 in human Dcs
ERK is often associated with migration, and therefore we tested 
ERK activation profiles in mature human DCs stimulated with 
either CCL19 or CCL21. Surprisingly, CCL21 induced more ERK 
activity than CCL19 (Figure 2). At 100 nM, CCL21 induced an 
approximately fourfold increase in pERK1/2 over cells stimulated 
with buffer, whereas the same amount of CCL19 only induced 
an approximately twofold increase (Figure  2C). The same 
tendency was seen at 1 and 10  nM chemokine concentrations 
(Figures 2A,B).
In order to determine G protein contribution to the MAP 
kinase activity, ERK activity was measured in the presence of 
pertussis toxin (PTx), a substance that inhibits Gαi irrevers-
ibly by ADP-ribosylation. As seen in Figure 2D, 10 μg/ml PTx 
completely abolished CCL19- and CCL21-induced ERK1/2 
activation in DCs, indicating that Gαi is the main mediator of 
CCR7-induced pERK1/2 activation in DCs.
Due to the established broad spectrum GAG binding of 
CCL21 through its C-terminal tail (12, 13), a local CCL21 
reservoir is expected to form at the DC surface, which may 
gradually become available for CCR7 activation through vari-
ous mechanisms, influencing the CCL21 ERK activation profile 
over time. Thus, we investigated time-dependent MAP kinase 
activation. At 10  nM chemokine concentrations, there was a 
tendency that CCL19-induced ERK activation at an earlier 
time-point than CCL21, which shows a tendency to peak later 
(Figure 2E). At 100 nM chemokine concentrations, ERK activa-
tion was in  general more pronounced. ERK activation by CCL21 
was prolonged and peaked at 50  min after induction (or even 
later), whereas that of CCL19 peaked earlier – at 30  min (or 
possibly before) (Figure 2F). The stronger CCL21-induced ERK 
FigUre 2 | erK1/2 activation in human dendritic cells in response to ccl19 and ccl21. Human DCs with natural CCR7 expression were used for the 
ERK1/2 activation. The percentage of phosphorylated ERK1/2 was calculated as described by the manufacturer (Meso Scale Discovery, MD, USA) as % 
Phosphoprotein = [(2 × Phospho-signal)/(Phospho-signal + Total signal)] × 100. The pERK1/2 data are normalized to buffer and displayed as fold ERK1/2 
activation over buffer control. (a–c) The effect of 1 nM (a), 10 nM (B), or 100 nM (c) of CCL19 and CCL21. (D) The effect of PTX (10 μg/ml) on ERK1/2 
activation by CCL19 and CCL21. (e) Timely effect of 10 nM and (F) 100 nM CCL19 and CCL21 on DC ERK1/2 phosphorylation. (g) The effect of 
neuraminidase (NA) treatment of DCs on ERK1/2 activation by CCL21 and (h) by CCL19. Statistical significance was calculated using unpaired t test. NS, not 
significant; *P < 0.05, **P < 0.01 (n = 3–6).
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activation giving rise to the hypothesis of CCL21 forming a local 
reservoir.
The GAG-subtype polysialic acid was recently shown to act 
as coreceptor for CCL21 during CCR7 activation (14), whereas 
others, e.g., chondroitin sulfate-B (CS-B) have been shown to 
inhibit CCL21 activity. To determine the impact of polysialic 
acid on CCL21-induced ERK activation, DCs were pretreated 
with NA that was also present during the experiment. Indeed, this 
FigUre 3 | response of the three naturally occurring chemokines 
(ccl19, ccl21, and tailless-ccl21) on 3D chemotaxis of human 
dendritic cells. (a) Column diagrams showing the directional migration of 
DCs in response to 10 nM and 100 nM of CCL19, CCL21, or tailless-CCL21 
source concentrations. The values are calculated as chemotactic index (CI) in 
the MATLAB software. (B) Column diagrams showing the pERK in response 
to 100 nM CCL19, CCL21, or tailless-CCL21 in neuraminidase treated DCs 
as percentage of the signal of the corresponding chemokine in non-
neuraminidase treated cells. Data are normalized, and all non-treated 
responses set to 100%. Statistical significance was calculated using unpaired 
t test. **P < 0.01, *P < 0.05, NS, not significant (n = 3).
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treatment negatively affected CCL21-induced ERK1/2 activation 
(Figure 2G), but not CCL19-induced activity (Figure 2H), sup-
porting an important role of polysialic acid in CCL21-induced 
CCR7 activation and thus ERK signaling in DCs.
Tailless-ccl21 is superior to ccl21 in 
inducing Dc Migration and also 
resembles ccl19 with regard to erK 
activation
Since the release of the C-terminal tail of CCL21 from its poly-
sialic acid interaction negatively affects CCL21-mediated ERK 
activation (Figure 2G), we wanted to investigate the role of the 
extended C-terminal tail of CCL21 in chemotaxis and therefore 
designed a truncated version of CCL21 lacking the C-terminus 
and investigated its properties in inducing 3D migration and ERK 
activation of human DCs.
Indeed, tailless-CCL21 was more potent than full-length 
CCL21 in inducing directed migration of DCs and at a concen-
tration of 10 nM induced chemotaxis with similar CI as CCL19 
(Figure 3A), whereas there was no significant difference between 
the three chemokines at 100  nM (Figure  3A). Tailless-CCL21 
also resembled CCL19 with regard to ERK activation and thus 
in contrast to what was observed for CCL21, neither CCL19 nor 
tailless-CCL21-induced ERK activation was affected by DC NA 
treatment (Figure 3B).
ccl21 Binds to the Dc surface Forming 
large and small Puncta
To test if CCL21 could be detected on the DC surface to a higher 
degree than tailless-CCL21, we performed immunostainings 
against the two chemokines on cells that had been incubated 
on ice with 100 nM of the respective chemokines. In contrast to 
tailless-CCL21, CCL21 localized to the DC membrane forming 
discrete puncta, whereas cells incubated in the absence of ligand 
were devoid of staining (Figures 4A–E). Membrane localization 
appeared as an extended rim around the cell that was not sharply 
defined due to the dendrites that make the membrane villi-like in 
appearance in non-adherent DCs (Figure 4D). CCL21 stainings 
in general took form of either a few large puncta or multiple small 
puncta, with both types of stainings following the rim of the cell 
(Figure  4E). Importantly, polyclonal antibody against CCL21 
recognized tailless-CCL21 to the same degree as it recognized 
CCL21 (Figure 4F).
ccl21 and Tailless-ccl21 are less 
Potent compared with ccl19 in g 
Protein-Mediated signaling and β-arrestin 
recruitment
Intrigued by the observations that tailless-CCL21 resembled 
CCL19 more than it resembled CCL21 in both migration and 
ERK activation, we investigated the potency of CCL19, CCL21, 
and tailless-CCL21 in inducing signaling pathways “closer” to 
the membrane (G protein activation, β-arrestin recruitment, and 
CCR7 internalization) as compared to the more downstream 
MAP kinase activation and migration.
The ability to induce signaling via Gαi – the major G protein 
pathway induced by endogenous chemokine receptors (27) – was 
investigated in a PI-turnover assay using HEK293 cells trans-
fected with CCR7 and the chimeric protein Gqi4myr that converts a 
Gαi-coupled response into a Gαq readout (24).
We found that the potency of CCL21 was ~10-fold lower com-
pared with that of CCL19 with an estimated EC50 of 50 nM (−log 
7.3 ± 0.18, n = 3) for CCL21 compared with 5 nM for CCL19 
(−log 8.3 ±  0.27, n =  3), and with no significant difference in 
efficacy between the two (Figure 5A). Surprisingly, in contrast to 
what was observed in migration (Figure 3A), tailless-CCL21 did 
not exhibit increased ability to signal via Gαi but displayed low 
activity in this pathway similar to full-length CCL21 (estimated 
EC50 of 142 nM).
To determine receptor mediated β-arrestin recruitment, 
CCR7 tagged at the C-terminus with the catalytic N-terminal 
domain of β-gal, also referred to as the enzyme donor fragment, 
was transiently transfected in U2OS cells stably expressing 
β-arrestin 2 fused to an N-terminal deletion mutant of β-gal, 
the enzyme acceptor fragment. The binding of β-arrestin 
2 to CCR7 reconstitutes donor and acceptor parts of β-gal 
into a functional enzyme and the readout was measured as 
chemiluminescence. As with Gαi signaling, CCL19 exhibited a 
significantly higher potency compared with CCL21 (~17-fold), 
and CCL21 only reached half of CCL19-induced activity at 
100  nM (Figure  5B). EC50 was estimated to 15  nM (−log 
7.8 ±  0.1, n =  3) for CCL19 and 263  nM (−log 6.6 ±  0.32, 
n =  3) for CCL21. Again, tailless-CCL21 was weak; in fact it 
did not induce β-arrestin 2 recruitment at concentrations up to 
100 nM. β-arrestin-mediated CCR7 internalization induced by 
CCL19 and CCL21 was measured in U2OS cells coexpressing 
untagged receptor DNA, β-arrestin 2 fused to the β-gal enzyme 
FigUre 4 | ccl21 binds to the surface of human Dcs and forms discrete puncta; a feature not matched by tailless-ccl21. Fluorescence microscopy 
pictures of DCs incubated (a) with100 nM CCL21, (B) 100 nM tailless-CCL21, or (c) in the absence of ligand obtained on LSM 780 confocal microscope using  
63× oil-objective (ligands were stained with Alexa 488 and the cell nucleus visualized with Hoecst DNA staining). (D) Zoom in on DC incubated with 100 nM CCL21 
to visualize that anti-CCL21 staining followed the villi-like surface of non-adherent DCs. (e) Visualization of two different types of CCL21 puncta. (F) The anti-CCL21 
antibody also recognized tailless-CCL21.
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acceptor fragment, and endosomes tagged with β-gal enzyme 
donor fragment. Tailless-CCL21 internalization was not investi-
gated due to lack of β-arrestin coupling. Quantitative fusion of 
β-arrestin and endosomes was detected as chemiluminescence. 
CCL21 induced internalization; however, only to ~40% of the 
level induced by CCL19 at 100  nM (Figure  5C). Its potency 
was also lower (~37-fold) with an EC50 estimated to 152  nM 
(−log 6.8 ±  0.08, n =  3) compared with 4.1  nM for CCL19 
(−log 8.4 ± 0.14, n = 3).
Thus CCL21 is weaker than CCL19 in G protein activation 
and β-arrestin recruitment, and tailless-CCL21 resembles CCL21 
more than CCL19 although it seems to be less potent compared 
with CCL21.
ccl19 and ccl21 Diverge in structure
The fact that tailless-CCL21 displays distinct properties compared 
with CCL19, and resembles CCL21 more with regard to upstream 
signaling events, implies that the tail of CCL21 plays no major 
role in controlling differences in CCL19 and CCL21 receptor 
engagement. In Figure 6A, a backbone solution structure (top) 
and a surface view (bottom) is presented of the NMR structure 
of CCL19 and CCL21, excluding the flexible C-terminal tail of 
CCL21 (28, 29). Considering overall structural and functional 
similarities between CCL19 and CCL21 (19–22), we compared 
the tertiary structures of these two chemokines. As the solution 
structure reveals, CCL21 maintains the triple-stranded beta-sheet 
and C-terminal alpha-helix typical to chemokines. The surface 
presentations underscore obvious differences between CCL19 and 
CCL21 in GAG but also in receptor docking domains. CCL21 has 
a much more pronounced clustering of positively charged amino 
acids in the GAG-binding domain, which probably facilitates 
the highly increased GAG-binding capability of this chemokine 
residing in the positively charged C-terminus extending directly 
from this region (Figure 6A), a feature not matched in CCL19. 
The primary sequence alignment (Figure 6B) highlights similari-
ties and charges of CCL19 and CCL21. The highly basic GAG-
binding tail of CCL21 clearly underscores the charge difference 
between CCL19 and CCL21 located to the GAG-binding domain.
It is generally believed that receptor activation occurs as a result 
of the N-terminal chemokine domain docking deep into the main 
binding pocket; a process thought to be a major contributor to the 
ligand-specific receptor activation mechanism (30, 31). CCL19 
has a slightly more negative and relatively smaller (721 versus 
649 Da) receptor docking domain compared with CCL21. Thus 
FigUre 5 | ccr7 g protein activation, β-arrestin recruitment, and internalization induced by ccl19, ccl21, and tailless-ccl21. (a) Dose–response 
curves of CCL19 (circles), CCL21 (squares), and tailless-CCL21 (triangles) obtained in PI-turnover assay measured in HEK293 cells cotransfected with CCR7 and 
the chimeric G protein Gqi4myr. Statistical significant difference from CCL19 was calculated by unpaired Student’s t-test. *P < 0.05, **P < 0.01, and NS, not 
significant. (B) β-arrestin recruitment measured in U2OS cells stably transfected with β-arrestin 2 linked to an enzyme acceptor and transiently transfected with 
enzyme donor-fused CCR7 with increasing concentrations of CCL19 (circles), CCL21 (squares), and tailless-CCL21 (triangles). Statistical significance between 
CCL19 and CCL21 values was calculated using unpaired t test. **P < 0.01. (c) β-Arrestin 2-dependent internalization measured in U2OS cells coexpressing 
untagged CCR7 DNA, β-arrestin 2 fused to the enzyme acceptor part of β-gal, and endosomes tagged with PK, the enzyme donor. Dose–response curves for 
CCL19 (circles) and CCL21 (squares) are shown. Statistical significance was calculated using unpaired t test (n = 3–4).
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differences in size and distribution of electronegativity in the 
N-terminal chemokine domain probably dictate different recep-
tor docking modes for CCL19 and CCL21.
ccl19 and ccl21 rely on Different 
amino acids for ccr7 engagement
To investigate possible differences in the docking of CCL19 and 
CCL21 during CCR7 activation, we introduced mutations in 
CCR7 in the main binding pocket, in areas previously identified 
to be involved in ligand binding. The impact of single point 
mutations for CCL19- and CCL21-induced receptor activation 
was measured in PI-turnover in HEK293 cells transiently trans-
fected with CCR7 and chimeric protein Gqi4myr (Figure 7). Most 
chemokine receptors carry a Glu in the top of TM7 (position 
VII:06/7.39) – a residue that function as an anchor for positively 
charged residues in chemokines as well as in small molecules (32). 
We use the generic numbering system suggested by Schwartz, fol-
lowed by the Ballesteros−Weinstein numbering system (33–35). 
As the only endogenous chemokine receptor, CCR7 carries a 
Tyr at this position (at the border between the major and minor 
binding pocket), and thus this residue could be of selective 
importance for CCR7 interaction with its ligands. Introduction 
of Glu (Y312E) resulted in a very high degree of constitutive 
activity, corresponding to 50% of Emax for CCL19 on wt CCR7, 
and completely abolished ligand-induced activation (Figure 7A). 
A subsequent substitution to Ala (Y312A) uncovered that this 
Tyr is not needed for ligand-induced activation, as both ligands 
induced CCR7 activity with wt-like potencies [CCL19: EC50 of 
5.4 nM (wt) and 7.8 nM (Y312A) and estimated CCL21: EC50 of 
156 nM (wt) and 77 nM (Y312A)] (Figure 7A). Like for Y312E, 
Y312A induced constitutive activity in CCR7 to a basal activity of 
30% of Emax for CCL19 on wt CCR7, demonstrating that the Tyr 
at position VII:06/7.39 restricts basal CCR7 activity – a property 
that ensures efficient migration toward a chemokine gradient.
Closer to the cell surface, helix 7 in CCR7 contains an acidic 
residue (Asp309VII:03/7.36) that could be envisioned to take over 
the usual role of Glu312VII:06/7.39 as chemokine recognition motif. 
Mutation of D309 to A (Figure  7B), revealed that Asp is not 
needed at this position for neither CCL19 nor CCL21 interaction 
with CCR7, in fact substitution with Ala increased the potency 
of both ligands, possibly due to removal of a negative charge that 
could repel the mildly acidic N-terminus of these ligands.
Mutation of K130III:02/73.24 to A, previously shown to affect both 
CCL19 and CCL21 signaling in CHO and COS-7 cells with up 
to 15-fold decreased potency (37), had no effect in our setup 
(Figure  7F). We used HEK293 cells and a different receptor 
construct (untagged CCR7 compared with C-terminally V5-his-
tagged CCR7), possibly explaining this difference. Also in our 
model of CCR7, K130 points away from the binding pocket, and it 
is therefore not included in our pocket view model (Figures 7G,H).
Mutagenesis of K137III:09/3.33 to A in the bottom of the major 
binding pocket, sheltered under ECL2 of TM3 has previously 
been shown to selectively lead to diminished CCL21-induced 
G protein signaling through CCR7 with up to 22-fold decrease 
in potency of CCL21 compared with less than 2.5-fold decrease 
for CCL19, whereas changing Q227V:08,5.42 to A in the top of TM5 
(same position on basolateral axis in major binding pocket, but 
further away from minor binding pocket than K137) affected 
both ligands with up to 20- and 28-fold decrease in potency for 
CCL19 and CCL21, respectively (37).
We confirm the data on K137A and Q227A (Figures 7C,F) 
and inferred that if this ligand selectivity reflects direct interac-
tion differences, more residues in this receptor region would be 
similarly selective, and define a CCL21 recognition domain.
Focusing on the area of the major binding pocket delimited 
by TM3, -4, and -5, we mutated Glu193IV:20/4.60 – another putative 
negatively charged CCR7 anchor point for CCL19 and CCL21 
(in the absence of any impact of Tyr312 and Asp 309 in TM7). 
Intriguingly, mutating E193 to A selectively impairs CCL21 
signaling, whereas it has the opposite effect (enforcement of 
signaling) on CCL19 (Figure 7D). Even the most conservative 
substitution to Asp (E193D) impaired CCR7 activation by CCL21 
FigUre 6 | structure and alignment of ccl19 and ccl21. (a) NMR solution structure of CCL21 (PDB reference 2L4N) and CCL19 (PDB reference 2MP1). 
Cartoon structures are aligned in PyMOL to demonstrate the secondary structures likely to be found in both proteins (top). Exposed charges of either structure are 
shown on the surface presentation (bottom) with positive charges in blue and negative charges in red. Pale blue and pale red represents surface-exposed 
nitrogen- and oxygen atoms, respectively. The lower line divides the chemokine core domain from the highly flexible N-terminus, whereas the upper line delimits the 
regions that most closely match the mark of a GAG-binding domain, i.e., a dense cluster of exposed positive charges. The light blue ellipse on CCL21 represents 
the large unsolved C-terminal tail, of which most is also removed in tailless-CCL21. (B) Amino acid sequence alignment of CCL19 and CCL21 using the MAFFT 
multiple-aligner plug-in of Geneious Pro 6.1.7 software (Biomatters Ltd., Auckland, New Zealand). The secondary structures are shown with symbols, using arrows 
for beta-strands and a cylinder for the alpha-helix. Identical residues are black, similar residues are gray, and positively and negatively charged residues are blue and 
red, respectively. The unsolved C-terminus of CCL21 is outlined in a light blue box.
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with no impairment of CCL19, indicating that the length of the 
negatively charged side chain matters, and that we manipulated 
a finely tuned CCL21 interaction domain. How K137 and E193 
affect CCL21 signaling is still open to interpretation; however, as 
they are positioned close to each other (Figure 7H), they likely 
affect CCL21 as a pair.
Having established that the top of TM3, -4, and -5 seems 
more important for CCL21 than for CCL19, primarily by 
FigUre 7 | site-directed mutagenesis scan of ccr7. (a–e) Dose–response curves of CCL19 (black squares) and CCL21 (white squares) on CCR7 WT (dotted 
line) and mutants obtained in PI-turnover assay measured in HEK293 cells cotransfected with CCR7 constructs and the chimeric G protein Gqi4myr. (a) Mutational 
analyses of position 312 (Y312E, upper panel and Y312A, lower panel). (B) Mutation of position 309 (D309A) and (c) position 137 (K137A). (D) Mutation of position 
193 (E193A, upper panel and E193D, lower panel). (e) Mutation of position 133 (F133A, upper panel and F133H, lower panel). (F) Effects of mutation K130A, 
K137A, and Q227A at 100 nM chemokine concentrations. Top (g) and side (h) view of the chemokine binding pocket of CCR7 based on homology-modeling from 
CCR5 (PDB reference 4MBS) (36) with helices indicated by roman letters. (g) Y312 is located at the border between the major (left) and minor (right) binding pocket, 
while D309 is located at the top of the minor binding pocket. A view into the major binding pocket presents the relative positions of F133, K137, and E193 (h). 
Middle section: serpentine model, upper panel, and helical wheel, lower panel of CCR7 with indication of the included mutations. Statistical significance in signaling 
through WT CCR7 and mutants with either CCL19 or CCL21 was calculated using unpaired t test. **P < 0.01, *P < 0.05 (n = 3–9).
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focusing on charged residues, we looked into an aromatic residue 
(Phe133 in position III:05/3.29) in TM3, located between the 
two identified lysines (K130 and K137) and pointing right into 
the binding crevice. When F133 was mutated to Ala (F133A), 
this too resulted in a CCR7 receptor selectively unresponsive to 
CCL21 (Figure 7E). Even substitution with a histidine that has 
FigUre 8 | Overview of differences in signaling induced by ccl19, 
ccl21, and tailless-ccl21. Schematic illustration of the relative effect of 
CCL19, CCL21, and tailless-CCL21 on diverse cellular effects presented in 
Figures 1–6. Thickness of arrows signifies effect, i.e., thick arrow, high 
activity; thin arrow, low activity.
TaBle 1 | Tailless-ccl21 depends on the same amino acid interactions 
as ccl21 for g-protein signaling.
WT ccr7 K137a e193a F133a
CCL21 57.0 ± 0.7 16.0 ± 3.3 19.3 ± 4.6 28.7 ± 7.0
Tailless-CCL21 42.7 ± 2.0 16.7 ± 5.1 17.5 ± 3.4 27.1 ± 10.3
Values annotate percentage activation of CCR7 (±SEM) in response to either CCL21 or 
tailless-CCL21 relative to CCL19.
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pseudo-aromatic properties, selectively interfered with CCL21 
signaling. This residue, neither as Phe nor His, could be an inter-
action partner of K137 or E193, and accumulating experimental 
evidence suggests that this small region constitutes a part of a 
selective and direct CCL21 recognition domain. Finally, amino 
acids shown to be important for CCL21 activation, without 
affecting CCL19 induced signaling, was shown to be of equal 
importance to tailless CCL21, indicating that these variants of 
CCL21 probably activate the receptor in the same way (Table 1).
DiscUssiOn
Bias is not uncommon in the chemokine system, as reviewed 
recently (18, 38). In addition to the present study in DCs and 
in experimental cell lines (summarized in Figure 8), ligand bias 
in CCR7 has been described in other cells (19–22). It has also 
been described for ligands acting on other endogenous [CXCR2, 
CXCR3, and CCR10 (18)] and viral chemokine receptors 
(39–41). Receptor bias has been described for instance in CCR5 
wt and variants, where the same ligand elicited different signals in 
a receptor-dependent manner and is also common among virus-
encoded receptors (42, 43). Tissue bias adds an extra dimension of 
complexity to the chemokine system with differential expression 
pattern in a spatial- and time-dependent manner for receptors 
and ligands (17, 18).
Investigating CCR7 bias, we chose to look at CCR7 in DCs 
that naturally express CCR7 and play a key role in both adaptive 
and acquired immunity. DC migration to lymph nodes dictated 
by CCR7 is of outmost importance for these processes. As the 
first, we show that CCL21 is less potent than CCL19 in induc-
ing chemotaxis of human DCs. This contrasts earlier studies in 
murine DCs reporting CCL21 to be more potent compared with 
CCL19 in steep chemokine gradients, whereas no difference was 
found in shallow gradients (44). Also, murine DCs were shown 
to preferentially migrate toward CCL21, in opposing gradients 
of CCL19 and CCL21. In support of our study, another group 
described preferential migration of murine DCs toward CCL19 
in a similar setup (15). In further support of our data, Ricart et al. 
found that in shallow gradients (≤  20  nM source concentra-
tions), CCL19-induced murine DC migration with a higher CI 
than CCL21, yet this was not the case at steep gradients (200 nM 
source concentrations) (45).
We show that tailless-CCL21 – a naturally occurring CCL21 
product formed by protease activity in DCs (15) – is equally potent 
to CCL19 in inducing DC chemotaxis, which is in agreement with 
recent findings (14). It could be speculated that CCL21 accumula-
tion on the DC surface through GAG binding generate a local 
reservoir that disturb DC gradient sensing. At very high CCL21 
concentrations the gradient may become visible again supplying 
higher CCL21 concentrations than what can be accumulated on 
the DC surface. Our data on chemokine localization on the mem-
brane shows that CCL21, but not tailless-CCL21 forms small and 
large puncta on the cell surface, consistent with an earlier study 
detecting CCL21 on the surface of cells transfected with CCR7 
(46). That study showed that the formation of puncta depends 
on both CCR7 and GAGs, indicating that the spots are clusters of 
CCL21-bound CCR7, probably in combination with GAGs. This 
supports our theory that CCR7 on the surface of DCs exposed 
to CCL21 is covered in ligand and thus may be unable to sense 
weak CCL21 gradients. In contrast, in cells exposed to CCL19, 
CCR7/CCL19 complexes are quickly internalized and whereas 
the ligand is degraded, CCR7 is recycled to the membrane for 
renewed ligand engagement.
We speculate that haptotactic CCL21 gradients, earlier shown 
to gather peri-lymphatic and lymphatic capillary DC migration 
toward collecting lymphatic vessels (47), are converted in situ to 
short-lived tailless-CCL21 gradients of higher potency. Thereby, 
the truncated form of CCL21 could potentiate the chemotactic 
signal in cases where many activated DCs move together, with the 
front runners paving the way for the rest of the DCs, by leaving 
a trail of cleaved (tailless) CCL2 (Figure 9). This could increase 
DC homing in situations with massive DC activation, e.g., during 
a severe infection.
Since ERK activation is coupled to migration (48) we inves-
tigated CCL19- and CCL21-induced ERK activation in DCs. 
The observed more efficient and prolonged ERK1/2 activation 
by CCL21 compared with CCL19 is in contrast to earlier 
studies in HEK293 cells, where CCL19 displayed higher (19) 
or similar efficacy (21) as CCL21. These differences could be 
due to variations in GAG distribution in human DCs versus 
HEK293 cells, as we find that CCL21 interaction with polysialic 
acid is important for DC signaling revealed by the impact of 
FigUre 9 | Model for diverse mechanisms of ccl19, ccl21, and tailless-ccl21 in regulation of ccr7 activation. As revealed by the structure 
comparison (Figure 5), CCL21 harbors structural motifs indicating a unique ability to strongly interact with GAGs, also supported by earlier reports. Increased GAG 
binding builds a local CCL21 reservoir at the cell surface, with CCL21 present in an inhibited, non-inhibited, or even facilitated form dependent on the GAG carrying 
it. In contrast, CCL19 only displays weak GAG interaction and readily diffuses away from the cell if not immediately bound to CCR7. GAG-bound CCL21 on the 
contrary, may either (i) interact directly with CCR7 if bound to polysialic acid, (ii) interact with CCR7 after GAG detachment caused by protease induced tail removal, 
with tailless-CCL21 probably being immediately ready for receptor engagement since release is expected to occur at the DC surface and thus in close proximity to 
CCR7 molecules ready to capture the chemokine, or (iii) interact with CCR7 after transfer from a GAG that presents CCL21 in its inhibited state (CS-B), to a GAG 
that allows CCR7 engagement (polysialic acid), with CS-B here acting as a dormant reservoir. CCL19 does not form a local reservoir, and once bound to CCR7, it 
gets quickly internalized and degraded, which is not the case for CCL21. Our model thus predicts that CCL19 and CCL21 induce differential CCR7 activation, with 
CCL19 creating a short-lived (temporary) signal, and CCL21 displaying a weaker, but more persistent CCR7 activation profile.
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NA treatment on CCL21-induced ERK1/2 activation. This treat-
ment interferes with CCL21 signaling possibly by preventing 
a local CCL21 reservoir at the DC surface needed for higher 
and prolonged ERK activation (Figure  9). It may also alter 
CCL21 structure, and thereby function, by unlocking of an 
auto-inhibited CCL21, as described recently (14). In general, 
our data do not contradict that ERK activation could be an 
important player in directing CCR7-induced chemotaxis. At 
least one study reports that CCR7-Gi mediated activation of 
MAP kinases, including p38 and ERK1/2, in response to either 
CCL19 or CCL21, is important for DC chemotaxis, but not 
migrational speed, that was mainly controlled by Rho (49). 
On the other hand, PGE2, that is a key player in inducing 
migration of human monocyte-derived DCs (50, 51) and human 
monocytes, potently inhibits ERK1/2 activation in the latter 
(52). Along these lines it has been reported that ERK activation 
keeps human DCs in an immature state and that ERK inhibition 
by UO126 increases the expression of CCR7 and stimulates 
migration toward CCL19 (53). Similarly, human cord blood DCs 
experience improved migration toward CCL19 upon treatment 
with UO126 (54). In our hands, UO126 neither inhibited nor 
enhanced chemotaxis induced by either CCL19 or CCL21 (data 
not shown). A role for the Rho pathway in stimulation of murine 
DC chemotaxis in  vitro and in  vivo is supported by several 
studies (55, 56), and thus numerous pathways may be involved 
in controlling DC chemotaxis, and they may not be the same 
in 2D and 3D settings.
Many groups have studied signaling and internalization of 
CCR7. CCL19 and CCL21 have been reported to have the same 
efficacy and potency in G protein activation (in H9 T cell lym-
phoma cells) (19) and Ca2+ flux (in L1.2 cells, a murine pre-B 
cell line) (57). We observed an approximately sevenfold lower 
potency of CCL21 in inducing G protein activation compared 
with CCL19, and found that tailless-CCL21 behaved more like 
CCL21, although it seemed to have an even lower potency. This 
is in line with recent data reporting limited intracellular Ca2+ 
mobilization in response to a soluble version of CCL21 compared 
with CCL19 and CCL21 in human DCs (58).
Others have also shown that CCL19 is more potent than 
CCL21 in inducing CCR7 phosphorylation and β-arrestin 2 
recruitment (19, 20). Consistent with earlier studies (19, 20, 
22, 57), we observe weak CCR7 internalization in response to 
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CCL21, whereas CCL19 induces strong β-arrestin 2-dependent 
internalization.
Importantly β-arrestin 1 and 2 coupling by CCR7 in response 
to both CCL19 and CCL21 seem to differentially affect ERK 
activation, with β-arrestin 1 coupling inhibiting ERK activation 
and β-arrestin 2 coupling stimulating ERK activation (21). That 
differential β-arrestin coupling by CCL19 and CCL21 dictates 
ligand bias is not likely, since differential β-arrestin-mediated 
phospho ERK is not observed between CCL19 and CCL21 (21).
Instead, differential recruitment of GRK molecules by CCR7 
in response to CCL19 and CCL21 could be an important player 
in controlling ERK ligand bias, thus GRK2 and GRK3 recruit-
ment by CCR7 in response to CCL19 negatively affects ERK 
activation, whereas these GRKs are not involved in controlling 
ERK activation induced by CCL21 (21). GRK6 knock down on 
the other hand was shown to potently inhibit ERK activation 
induced by both CCL19 and CCL21, and thus it seems the relative 
recruitment of GRK2, GRK3, and GRK6 is very important for 
determining ERK activation via CCL19, whereas the amount of 
GRK6 recruitment by CCR7 determines CCL21-induced ERK 
activation through this receptor.
As internalized CCR7 is recycled to the cell surface, while 
CCL19 is targeted for lysosomal degradation (20), it is conceiv-
able, that CCL19-induced CCR7 endocytosis function as a 
negative feedback loop for CCL19, which is secreted by DCs 
(59), to prevent uncontrolled autocrine signaling. This may cause 
CCL19-mediated signaling to be temporal compared with that 
of CCL21 (Figure  9). Under normal circumstances, autocrine 
CCL19 is unlikely to influence DC lymph node homing, since 
CCL19 secretion from DCs is initiated after lymph node arrival 
(60). More likely, DC-secreted CCL19 serves as T-cell attractant 
controlling scanning behavior of naïve T-cells to increase cognate 
MHC-peptide encounter (61).
Our comprehensive structure comparison of CCL19 and 
CCL21 reveals that in addition to the elongated basic C-terminus, 
CCL21 contains a highly basic cluster of amino acids in the 
predicted GAG-binding area, not matched in CCL19 (Figure 6). 
This possibly adds to the unique ability of CCL21 to strongly 
interact with GAGs (12). Only CCL21, not CCL19, binds to 
chondroitin sulfate-B (CS-B) (62, 63), and whereas this binding 
inhibits CCL21-induced signaling, binding to heparan sulfate 
(HS) does not (62, 63). Similarly, the glycan polysialic acid was 
recently proven to act as important coreceptor for CCL21 (14). 
In contrast to CS-B and HS, polysialic acid is very restricted in 
its expression and apart from on neurons, where it regulates, 
e.g., migration, it is found mainly on leukocytes and DCs (14, 
64, 65). The different roles of specific GAGs in regulating CCR7 
activity, adds to the complexity of tissue bias. Our data suggests 
that the CCL21:GAG interaction is central for the different bio-
logical responses in DCs (Figure 9). Since mature DCs express a 
mixture of various GAGs on their surfaces, including CS-B, HS, 
and polysialic acid (65, 66), CCL21 captured on the surface of 
DCs may be presented in either an inhibited, non-inhibited, or 
even facilitated form dependent on the GAG carrying it. In addi-
tion, DC protease activity (15) likely alters the balance between 
free and GAG-coupled CCL21, potentially also influencing 
CCL21 activity. The GAG-tethered CCL21 on the DC surface 
may function as a local chemokine source that may (A) activate 
CCR7 directly or (B) become gradually available for receptor 
binding and activation by the DC to which it was tethered or 
DCs in the vicinity, either upon transfer between different GAG 
types or through gradually cleavage and release from inhibitory 
GAGs by endogenous proteases. Continuous release of CCL21 
could potentially lead to a more continuous activation of CCR7, 
explaining the higher and prolonged ERK1/2 activation profile 
induced by this chemokine.
In summary, we present new data supporting a model in which 
CCL19- and CCL21-mediated CCR7 activation in DCs employ the 
same signaling pathways, but CCL19 is a temporal signal compared 
with CCL21, which is more persistent (Figure  9). This fits well 
with homing mediated via CCL21 as a prolonged process, whereas 
T-cell scanning mediated via CCL19 needs to be short-lived allow-
ing for T-cells to quickly move around between different DCs. In 
addition we define tailless-CCL21 as a physiological relevant, 
functionally distinct chemokine probably equally important in 
controlling immune cell functions as CCL19 and CCL21. A central 
perspective of the present work is that since CCL19, CCL21, and 
tailless-CCL21 seem to activate CCR7 in different ways, it opens 
up the possibility of designing drugs that interfere with CCR7 
signaling in a ligand-specific manner. CCR7 has been shown to 
drive cancer and to be involved in multiple sclerosis progression 
and development of graft-versus-host disease thus playing a dual 
role in health and disease (67–71). Biased drugs targeting specific 
ligands or signaling events of CCR7 could be a future solution in 
disease settings with aberrant CCR7 signaling. By targeting a sub-
set of ligands or signaling paths, side effects caused by unwanted 
interference with beneficial CCR7 signaling important for normal 
immune responses in the patient could be avoided.
Future drugs designed to affect CCR7 signaling could target 
(1) the area between the minor and major binding pocket in this 
study represented by Y312 that upon mutation to either E or 
A confers massive constitutive activity to CCR7, identifying this 
area as an activity hot-spot, (2) the major binding pocket affecting 
mainly CCL21 receptor docking, thus enabling differentiation 
between CCL19 and CCL21, (3) GAG-binding obstructing 
CCL21-specific effects, without affecting tailless-CCL21 func-
tion, or finally (4) endogenous protease function or expression 
affecting only tailless-CCL21.
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